Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

July 24, 2012
Taiho Pharmaceutical

Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent
July 19, 2012
Otsuka Pharmaceutical

Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
July 19, 2012
Otsuka Pharmaceutical

Otsuka Pharmaceutical To Boost Production Capacity and Increase Sales with Third Pocari Sweat Plant in Guandong Province,China
July 13, 2012
Otsuka Holdings

Otsuka Holdings Announces Personnel Changes (Resignation) of Representative Director
July 11, 2012
Taiho Pharmaceutical

Business Partnership regarding Breakthrough Cancer Pain Reliever “OVF”
July 6, 2012
Otsuka Pharmaceutical

Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
July 3, 2012
Otsuka Holdings

Notice regarding Status of Acquisition of Own Shares
June 29, 2012
Otsuka Pharmaceutical

Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
June 29, 2012
Otsuka Holdings

Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
June 26, 2012
Otsuka Pharmaceutical

Reverse Daylight Savings Program to Shift Peak Energy Consumption
June 22, 2012
Taiho Pharmaceutical

Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet)
June 21, 2012
Otsuka Pharmaceutical

UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra® Tablet; New Dry Syrup Formulation Filed at the Same Time
June 15, 2012
Otsuka Holdings

Notice of the Result of Share Repurchase through ToSTNeT-3
June 14, 2012
Otsuka Pharmaceutical

Otsuka Pharmaceutical to Participate as Core Partner in TEDxTokyo 2012 to Connect Innovative Ideas to the Future
June 14, 2012
Otsuka Holdings

Notice of Acquisition of Own Shares through ToSTNeT-3
June 13, 2012
Otsuka Holdings

Otsuka Holdings Co., Ltd. to Acquire Own Shares
June 7, 2012
Otsuka Pharmaceutical

The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
June 6, 2012
Taiho Pharmaceutical

Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)
May 31, 2012
Taiho Pharmaceutical

Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102
May 11, 2012
Otsuka Holdings

Otsuka Holdings Announces Personnel Changes
May 8, 2012
Otsuka Pharmaceutical

The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka's Patent to ABILIFY®
May 8, 2012
Otsuka Pharmaceutical

Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
May 8, 2012
Otsuka Holdings

RESULTS FROM A PHASE 3 STUDY OF ONCE-MONTHLY ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT FORMULATION FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA PRESENTED AT APA ANNUAL MEETING
April 27, 2012
Otsuka Holdings

Otsuka announces 2012 first quarter U.S. net sales figures of ABILIFY®
April 17, 2012
Otsuka Pharmaceutical

New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence
April 16, 2012
Taiho Pharmaceutical

Distributor change for Lentinan I.V. Infusion 1 mg “Ajinomoto”, an anti-tumor agent
April 11, 2012
Taiho Pharmaceutical

Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.
April 11, 2012
Taiho Pharmaceutical

Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Hong Kong
March 30, 2012
Taiho Pharmaceutical

Termination of co-development of a β3-adrenoceptor agon
March 27, 2012
Otsuka Pharmaceutical

Gérlinéa to Launch Nationwide −Enjoyable Calorie Control without Giving Up Sweetness−